Clinical course and outcomes of diagnosing Inflammatory Bowel Disease in children 10 years and under: retrospective cohort study from two tertiary centres in the United Kingdom and in Italy

BMC Gastroenterol. 2016 Mar 15:16:35. doi: 10.1186/s12876-016-0455-y.

Abstract

Background: Most children with Inflammatory Bowel Disease (IBD) are diagnosed between 11 and 16 years of age, commonly presenting with features of typical IBD. Children with onset of gut inflammation under 5 years of age often have a different underlying pathophysiology, one that is genetically and phenotypically distinct from other children with IBD. We therefore set out to assess whether children diagnosed after the age of 5 years, but before the age of 11, have a different clinical presentation and outcome when compared to those presenting later.

Methods: Retrospective cohort study conducted at two European Paediatric Gastroenterology Units. Two cohorts of children with IBD (total number = 160) were compared: 80 children diagnosed between 5 and 10 years (Group A), versus 80 children diagnosed between 11 and 16 (Group B). Statistical analysis included multiple logistic regression.

Results: Group A presented with a greater disease activity (p = 0.05 for Crohn's disease (CD), p = 0.03 for Ulcerative Colitis (UC); Odds Ratio 1.09, 95 % Confidence Interval: 1.02-1.1), and disease extent (L2 location more frequent amongst Group A children with CD (p = 0.05)). No significant differences were observed between age groups in terms of gastro-intestinal and extra-intestinal signs and symptoms at disease presentation, nor was there a difference in the number of hospitalisations due to relapsing IBD during follow-up. However, children in Group A were treated earlier with immunosuppressants and had more frequent endoscopic assessments.

Conclusion: While clinicians feel children between 5 and 10 years of age have a more severe disease course than adolescents, our analysis also suggests a greater disease burden in this age group. Nevertheless, randomized trials to document longer-term clinical outcomes are urgently needed, in order to address the question whether a younger age at disease onset should prompt per se a more "aggressive" treatment. We speculate that non-clinical factors (e.g. genetics, epigenetics) may have more potential to predict longer term outcome than simple clinical measures such as age at diagnosis.

Keywords: Age; Children; Inflammatory Bowel Disease (IBD); Location; Outcomes; Presentation; Severity.

MeSH terms

  • Adalimumab / therapeutic use
  • Adolescent
  • Adrenal Cortex Hormones / therapeutic use
  • Age of Onset
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Inflammatory Agents / therapeutic use
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Cohort Studies
  • Colitis, Ulcerative / blood
  • Colitis, Ulcerative / epidemiology
  • Colitis, Ulcerative / physiopathology*
  • Colitis, Ulcerative / therapy
  • Crohn Disease / blood
  • Crohn Disease / epidemiology
  • Crohn Disease / physiopathology*
  • Crohn Disease / therapy
  • Digestive System Surgical Procedures
  • Disease Progression
  • Female
  • Hematocrit
  • Hemoglobins
  • Hospitalization / statistics & numerical data
  • Humans
  • Inflammatory Bowel Diseases / blood
  • Inflammatory Bowel Diseases / epidemiology
  • Inflammatory Bowel Diseases / physiopathology
  • Inflammatory Bowel Diseases / therapy
  • Infliximab / therapeutic use
  • Italy / epidemiology
  • Leukocyte Count
  • Logistic Models
  • Male
  • Mesalamine / therapeutic use
  • Platelet Count
  • Retrospective Studies
  • Severity of Illness Index
  • Tertiary Care Centers
  • United Kingdom / epidemiology

Substances

  • Adrenal Cortex Hormones
  • Anti-Bacterial Agents
  • Anti-Inflammatory Agents
  • Hemoglobins
  • Mesalamine
  • Infliximab
  • Adalimumab

Supplementary concepts

  • Pediatric Crohn's disease
  • Pediatric ulcerative colitis